中国基层医药
中國基層醫藥
중국기층의약
CHINESE JOURNAL OF PRIMARY MEDICINE AND PHARMACY
2013年
1期
13-15
,共3页
种族世系%前列腺肿瘤%肿瘤转移%锶%放射性同位素
種族世繫%前列腺腫瘤%腫瘤轉移%鍶%放射性同位素
충족세계%전렬선종류%종류전이%송%방사성동위소
Racial stoks%Prostatic neoplasms%Neoplasm metastasis%Strontium%Radioisotopes
目的 对比分析维吾尔族与汉族前列腺癌骨转移患者应用氯化锶(89 SrCl)的疗效.方法 36例维吾尔族和40例汉族前列腺癌骨转移患者89 SrCl静脉注射后,观察其镇痛效果、骨转移灶、前列腺特异性抗原(PSA)和白细胞介素-6(IL-6)的变化.结果 经89 SrCl治疗后,与汉族前列腺癌骨转移患者相比,维吾尔族患者镇痛效率(83.33％)和游离前列腺特异性抗原(F-PSA)[(29.29±8.69) μg/L]、总前列腺特异性抗原(T-PSA)[(3.73±1.48) μg/L]明显增高,差异均有统计学意义(x2=4.113,t=1.359,t=1.849,均P＜0.05).结论 与汉族前列腺癌骨转移患者相比,维吾尔族患者对89SrCl的治疗效果更好.
目的 對比分析維吾爾族與漢族前列腺癌骨轉移患者應用氯化鍶(89 SrCl)的療效.方法 36例維吾爾族和40例漢族前列腺癌骨轉移患者89 SrCl靜脈註射後,觀察其鎮痛效果、骨轉移竈、前列腺特異性抗原(PSA)和白細胞介素-6(IL-6)的變化.結果 經89 SrCl治療後,與漢族前列腺癌骨轉移患者相比,維吾爾族患者鎮痛效率(83.33％)和遊離前列腺特異性抗原(F-PSA)[(29.29±8.69) μg/L]、總前列腺特異性抗原(T-PSA)[(3.73±1.48) μg/L]明顯增高,差異均有統計學意義(x2=4.113,t=1.359,t=1.849,均P＜0.05).結論 與漢族前列腺癌骨轉移患者相比,維吾爾族患者對89SrCl的治療效果更好.
목적 대비분석유오이족여한족전렬선암골전이환자응용록화송(89 SrCl)적료효.방법 36례유오이족화40례한족전렬선암골전이환자89 SrCl정맥주사후,관찰기진통효과、골전이조、전렬선특이성항원(PSA)화백세포개소-6(IL-6)적변화.결과 경89 SrCl치료후,여한족전렬선암골전이환자상비,유오이족환자진통효솔(83.33％)화유리전렬선특이성항원(F-PSA)[(29.29±8.69) μg/L]、총전렬선특이성항원(T-PSA)[(3.73±1.48) μg/L]명현증고,차이균유통계학의의(x2=4.113,t=1.359,t=1.849,균P＜0.05).결론 여한족전렬선암골전이환자상비,유오이족환자대89SrCl적치료효과경호.
Objective To analyze the effect on prostate cancer bone metastasis of Uygur and Han people treated with strontium-89-chlovide.Methods The curative effects in 36 cases of Uygur and 40 cases of Han patients with prostate cancer bone metastasis were investigated after intravenous injection with strontium-89-chloride,including palliation of pain,change of metastatic focus,level of prostate-specific antigen (PSA) and interleukin-6 (IL-6).Results After treated with strontium-89-chlovide,compared with the han patients with prostate cancer bone metastasis,the palliation rate (83.33 ％) F-PSA [(29.29 ± 8.69) μg/L] and T-PSA [(3.73 ± 1.48) ml/L] were higher,the bone metastases and the level of IL-6 were more significantly reduced of Uygur patients,and there were statistically significant (x2 =4.113,t =1.359,t =1.849,all P ＜ 0.05).Conclusion It is more effective treated with 89 SrCl-chloride for the Uygur patients with prostate cancer bone metastasis metastases than the Han patients.
